Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 known ✓ | P00734 | 18/20 | 0.67 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.67 |
| ▸ | AGTR1 known ✓ | P30556 | 1/20 | 0.67 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.67 |
| ▸ | NQO2 | P16083 | 2/20 | 0.78 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.67 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.67 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.64 |
| ▸ | F10 | P00742 | 1/20 | 0.64 |
| ▸ | PLG | P00747 | 1/20 | 0.64 |
| ▸ | PLAT | P00750 | 1/20 | 0.64 |
| ▸ | PROC | P04070 | 1/20 | 0.64 |
| ▸ | HPN | P05981 | 1/20 | 0.64 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.64 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.64 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.64 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.64 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL505917 | 0.97 | NQO2 (0.82) | NQO2F2NR1I2ADORA3SLC6A2 | |
| Hydrochloric Acid SCHEMBL14696865 | 0.97 | NQO2 (0.81) | NQO2F2NR1I2ADORA3SLC6A2 | |
| Oxalic Acid SCHEMBL13684738 | 0.95 | NQO2 (0.79) | NQO2F2NR1I2ADORA3SLC6A2 | |
| Acetic Acid SCHEMBL17065501 | 0.95 | NQO2 (0.79) | NQO2F2NR1I2ADORA3SLC6A2 | |
| Fumaric Acid SCHEMBL15415353 | 0.93 | NQO2 (0.76) | NQO2F2NR1I2ADORA3SLC6A2 | |
| SCHEMBL20211337 | 0.92 | NQO2 (0.67) | NQO2F2NR1I2ADORA3SLC6A2 | |
| SCHEMBL20211338 | 0.92 | F2 (0.76) | NQO2F2NR1I2ADORA3SLC6A2 | |
| SCHEMBL6779120 | 0.91 | NQO2 (0.71) | NQO2F2NR1I2ADORA3SLC6A2 | |
| Dabigatran Ethyl Ester SCHEMBL16583204 | 0.90 | NQO2 (0.94) | NQO2F2NR1I2ADORA3SLC6A2 | |
| SCHEMBL6780244 | 0.90 | NQO2 (0.70) | NQO2F2NR1I2ADORA3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2834224-B1 | PROCESS FOR THE PREPARATION OF BENZIMIDAZOLE DERIVATIVES AND SALTS THEREOF | MSN LAB LTD (IN) | 2018-06-06 | — | — | EP | claimed |
| US-20150087842-A1 | Process For The Preparation Of Benzimidazole Derivatives And Salts Thereof | MSN LABORATORIES PRIVATE LIMITED (IN) | 2015-03-26 | — | — | US | claimed |
| EP-2834224-B1 | PROCESS FOR THE PREPARATION OF BENZIMIDAZOLE DERIVATIVES AND SALTS THEREOF | MSN LAB LTD (IN) | 2018-06-06 | — | — | EP | disclosed |
| US-9273030-B2 | Process for the preparation of benzimidazole derivatives and salts thereof | MSN LABORATORIES PRIVATE LIMITED (IN) | 2016-03-01 | — | — | US | disclosed |
| US-20150366813-A1 | LIQUID-FILLED IMMEDIATE RELEASE SOFT GELATIN CAPSULES | PATHEON SOFTGELS INC | 2015-12-24 | — | — | US | disclosed |
| US-20150087842-A1 | Process For The Preparation Of Benzimidazole Derivatives And Salts Thereof | MSN LABORATORIES PRIVATE LIMITED (IN) | 2015-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087842-A1 | Process For The Preparation Of Benzimidazole Derivatives And Salts Thereof | AZI2, IL4I1, ABAT | F2 4142/4885SLC6A2 2353/4885AGTR1 3353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.